Physician profile
Thomas Mathews
NPI 1316926421
$4,184.06
in general payments reported to CMS, 2019-2025
12 companies · $1,217 in 2025
The $1,217 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $221 · 2021: $178 · 2022: $1,504 · 2023: $460 · 2024: $450 · 2025: $1,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,127.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $1,131.49 | 2022 | |
| Stryker Corporation | $768.52 | 2025 | Mako, Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Inari Medical, INC. | $661.15 | 2023-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abbott Laboratories | $490.31 | 2019-2025 | Cardiomems |
| Medtronic, INC. | $320.75 | 2021-2025 | Linq II, Micra, Symplicity G3 |
| Terumo Medical Corporation | $304.92 | 2022 | |
| Boston Scientific Corporation | $237.50 | 2022-2025 | Watchman Access System, Varithena Administration Pack, General - Brady |
| Artivion, INC. | $105.69 | 2021 | |
| Organogenesis INC. | $63.27 | 2023 | Puraply |
| Cardiovascular Systems INC. | $43.47 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $30.78 | 2023 | Dupixent |
| Shockwave Medical, INC | $26.21 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mathews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.